Article
Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance
1 May 2022
Abstract excerpt
Background: Tyrosine kinase inhibitor (TKI) treatment has significantly improved the prognosis of oncogenic-driven lung adenocarcinoma (LUAD). However, drug resistance limits the long-term benefits of patients. Therefore, there is a pressing need to explore the mechanism of TKI resistance and identify new therapeutic targets. It is possible to overcome TKI resistance by inducing tumor cell death through a new...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
